{"id":8462,"date":"2020-02-17T17:40:49","date_gmt":"2020-02-17T12:10:49","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8462"},"modified":"2024-09-18T15:29:59","modified_gmt":"2024-09-18T09:59:59","slug":"wet-age-related-macular-degeneration-treatment-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/wet-age-related-macular-degeneration-treatment-market","title":{"rendered":"Promising therapies that might shift Wet Age-related Macular Degeneration Market in the next decade"},"content":{"rendered":"\n

With no effective cure in Wet Age-related macular degeneration (Wet AMD) treatment market<\/a>, the need of new therapies that can not only slow down the progression of the vision loss but also kill the cause behind the degeneration of the macula. The present treatment approach requires intravitreal injection of anti-VEGF chemical to halt the development of extra blood vessels over macula that deteriorate the vision, which is one of the biggest Wet Age-related macular degeneration treatment market<\/a> barriers. <\/p>\n\n\n\n

However, with the rise in geriatric population, and advancement in R&D, the number of companies fueling the wet-age related treatment market has increased in the years. With several clinical trials ongoing and completed, a good number of pharma players are investing in wet age-related macular degeneration treatment market. Some of them include Allergan<\/strong>, Bioeq<\/strong>, Alkahest<\/strong>, GrayBug<\/strong> Vision<\/strong>, Eye<\/strong> point<\/strong> pharma<\/strong>, Innovent<\/strong> Biologics<\/strong>, Kodiak<\/strong> Sciences<\/strong>, Opthea<\/strong> PanOptica<\/strong>, Adverum<\/strong> Biotechnologies<\/strong> and several others. <\/p>\n\n\n\n

Herein are some of the therapies in the Wet Age-related macular degeneration pipeline<\/a> that are anticipated to bring a positive change in the Wet AMD treatment market in the next decade. <\/p>\n\n\n\n

Name: Abicipar pegol<\/strong>
Company: Allergan <\/strong>
MoA: Vascular endothelial growth factor A inhibitors
Status: Phase III
RoA: Intra\u2010vitreal injection<\/p>\n\n\n\n

Name: FYB201<\/strong>
Company: Bioeq<\/strong>
MoA: Vascular endothelial growth factor A inhibitors
Status: Phase III Completed
RoA: Intra\u2010vitreal injection.<\/p>\n\n\n\n

Name: GB-102<\/strong>
Company: Graybug Vision<\/strong>
MoA: Vascular endothelial growth factor A inhibitors
Status: Phase IIb
RoA: Intravitreal injection<\/p>\n\n\n\n

Name: Vorolanib<\/strong>
Company: EyePoint Pharmaceuticals<\/strong>
MoA: Vascular endothelial growth factor receptor antagonists
Status: Phase II
RoA: Oral therapy<\/p>\n\n\n\n

Name: IBI 302<\/strong>
Company: Innovent Biologics<\/strong>
MoA: Anti-VEGF therapy
Status: Phase I
RoA: Intravitreal injection<\/p>\n\n\n\n

Name: KSI-301<\/strong>
Company: Kodiak Sciences<\/strong>
MoA: Novel anti-VEGF biologic
Status: Phase 1b
RoA: Intravitreal injections<\/p>\n\n\n\n

Name: OPT-302<\/strong>
Company: Opthea<\/strong>
MoA: VEGF-A inhibitor
Status: Phase IIb
RoA: Intravitreal administration<\/p>\n\n\n\n

Name: PAN-90806<\/strong>
Company: PanOptica<\/strong>
MoA: Tyrosine kinase inhibitor
Status: Phase 1\/2
RoA: Anti-VEGF Eye Drop<\/p>\n\n\n\n

Name: ADVM-022<\/strong>
Company: Adverum Biotechnologies<\/strong>
MoA: AAV-anti-VEGF gene therapy
Status: Phase 1\/2
RoA: Intravitreal (IVT) administration<\/p>\n\n\n\n

As per DelveInsight\u2019s analysis, of all the Wet AMD emerging therapies<\/a>, the most anticipated product to get launched is Abicipar Pegol, a lead candidate of Allergan. With several other therapies in the horizon to get launched, the Wet Age-related macular degeneration treatment market is anticipated to increase at an advanced pace in the forecast period. <\/p>\n","protected":false},"excerpt":{"rendered":"

With no effective cure in Wet Age-related macular degeneration (Wet AMD) treatment market, the need of new therapies that can not only slow down the progression of the vision loss but also kill the cause behind the degeneration of the macula. The present treatment approach requires intravitreal injection of anti-VEGF chemical to halt the development […]<\/p>\n","protected":false},"author":1,"featured_media":8466,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[17098,18050,70,18049,18051,17099,1315,1806,18052,18053],"industry":[17225],"therapeutic_areas":[17244],"class_list":["post-8462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-adverum-biotechnologies","tag-alkahest","tag-allergan","tag-bioeq","tag-eye-point-pharma","tag-graybug-vision","tag-innovent-biologics","tag-kodiak-sciences","tag-opthea-panoptica","tag-wet-amd-emerging-therapies","industry-pharmaceutical","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"\nWet Age-related Macular Degeneration Treatment Market<\/title>\n<meta name=\"description\" content=\"DelveInsight estimates Abicipar Pegol, (Allergan), is going to occupy a maximum share of Wet Age-related macular degeneration treatment market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/wet-age-related-macular-degeneration-treatment-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wet Age-related Macular Degeneration Treatment Market\" \/>\n<meta property=\"og:description\" content=\"DelveInsight estimates Abicipar Pegol, (Allergan), is going to occupy a maximum share of Wet Age-related macular degeneration treatment market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/wet-age-related-macular-degeneration-treatment-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-17T12:10:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T09:59:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/17173453\/Promising-therapies.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Wet Age-related Macular Degeneration Treatment Market","description":"DelveInsight estimates Abicipar Pegol, (Allergan), is going to occupy a maximum share of Wet Age-related macular degeneration treatment market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/wet-age-related-macular-degeneration-treatment-market","og_locale":"en_US","og_type":"article","og_title":"Wet Age-related Macular Degeneration Treatment Market","og_description":"DelveInsight estimates Abicipar Pegol, (Allergan), is going to occupy a maximum share of Wet Age-related macular degeneration treatment market.","og_url":"https:\/\/www.delveinsight.com\/blog\/wet-age-related-macular-degeneration-treatment-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-02-17T12:10:49+00:00","article_modified_time":"2024-09-18T09:59:59+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/17173453\/Promising-therapies.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/wet-age-related-macular-degeneration-treatment-market","url":"https:\/\/www.delveinsight.com\/blog\/wet-age-related-macular-degeneration-treatment-market","name":"Wet Age-related Macular Degeneration Treatment Market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/wet-age-related-macular-degeneration-treatment-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/wet-age-related-macular-degeneration-treatment-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/17173453\/Promising-therapies.jpg","datePublished":"2020-02-17T12:10:49+00:00","dateModified":"2024-09-18T09:59:59+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"DelveInsight estimates Abicipar Pegol, (Allergan), is going to occupy a maximum share of Wet Age-related macular degeneration treatment market.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/wet-age-related-macular-degeneration-treatment-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/wet-age-related-macular-degeneration-treatment-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/17173453\/Promising-therapies.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/17173453\/Promising-therapies.jpg","width":772,"height":482,"caption":"Wet Age-related macular degeneration treatment market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/17173453\/Promising-therapies-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Adverum Biotechnologies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alkahest<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Allergan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Bioeq<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Eye point pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Graybug Vision<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Innovent Biologics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Kodiak Sciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Opthea PanOptica<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wet AMD Emerging Therapies<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Adverum Biotechnologies<\/span>","<span class=\"advgb-post-tax-term\">Alkahest<\/span>","<span class=\"advgb-post-tax-term\">Allergan<\/span>","<span class=\"advgb-post-tax-term\">Bioeq<\/span>","<span class=\"advgb-post-tax-term\">Eye point pharma<\/span>","<span class=\"advgb-post-tax-term\">Graybug Vision<\/span>","<span class=\"advgb-post-tax-term\">Innovent Biologics<\/span>","<span class=\"advgb-post-tax-term\">Kodiak Sciences<\/span>","<span class=\"advgb-post-tax-term\">Opthea PanOptica<\/span>","<span class=\"advgb-post-tax-term\">Wet AMD Emerging Therapies<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Feb 17, 2020","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Feb 17, 2020 5:40 pm","modified":"Updated on Sep 18, 2024 3:29 pm"},"featured_img_caption":"Wet Age-related macular degeneration treatment market ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8462"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8462\/revisions"}],"predecessor-version":[{"id":29643,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8462\/revisions\/29643"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8466"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8462"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8462"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}